Results 241 to 250 of about 283,642 (353)

From Droplet to Diagnosis: Spatio‐Temporal Pattern Recognition in Drying Biofluids

open access: yesAdvanced Intelligent Systems, EarlyView.
This article integrates machine learning (ML) with the spatio‐temporal evolution of biofluid droplets to reveal how drying and self‐assembly encode distinctive compositional fingerprints. By leveraging textural features and interpretable ML, it achieves robust classification of blood abnormalities with over 95% accuracy.
Anusuya Pal   +2 more
wiley   +1 more source

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs   +8 more
wiley   +1 more source

Blood Coagulation in Uremic Patients Before and After Hemodialysis and Transplantation of the Kidney [PDF]

open access: yes, 1966
Marchioro, TL   +4 more
core   +1 more source

Proteomic Analysis of Golden Sputum Reveals Pulmonary Complement Activation During Acute Chest Syndrome in Children With Sickle Cell Disease

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Acute chest syndrome (ACS) is one of the most common severe complications of sickle cell disease (SCD). In recent years, a major role of inflammation and innate immunity has been evidenced, but ACS pathophysiology remains incompletely understood, and therapeutic options are limited.
Slimane Allali   +14 more
wiley   +1 more source

Mean platelet volume as a biomarker of anemia and platelet disorders among metabolic syndrome patients in Northwest Ethiopia. [PDF]

open access: yesSci Rep
Kelem A   +8 more
europepmc   +1 more source

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy